Literature DB >> 9810580

[Patellar substitution in total knee prosthesis--is it important?].

M P Arnold1, N F Friederich, H Widmer, W Müller.   

Abstract

As shown in long term follow-up studies of Total Knee Arthroplasty (TKA), the femoropatellar joint is an important problem. We report our experience over the past seven years not having resurfaced the patella at the primary TKA at all. Between 1990 and 1997 more than 700 consecutive TKA with the De Puy New Jersey LCS prosthesis were performed. A standardised lateral approach with osteotomy of the tibial tuberosity was used. The patella was redressed, either denervated or left untouched. In no case a primary patellar resurfacing was performed. X-rays of the patello-femoral joint showed a remodelling of the patella over the years, nicely matching the condylar design of the femoral prosthesis. Using a blood-supply-preserving approach and a biomechanically adequate implant, TKA without patellar replacement gives excellent long-term results.

Entities:  

Mesh:

Year:  1998        PMID: 9810580

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  3 in total

1.  [Lateral approach to the knee combined with an osteotomy of the tibial tuberosity. Its use for total knee replacement].

Authors:  M P Arnold; N F Friederich; H Widmer; W Müller
Journal:  Oper Orthop Traumatol       Date:  1999-09       Impact factor: 1.154

2.  Medium-term evaluation of total knee arthroplasty without patellar replacement.

Authors:  José Wanderley Vasconcelos; Leopoldina Milanez da Silva Leite; José Carlos Amaral Sousa; José Orleans Mendes de Sousa; Márcio Fernandes Santos E Santos
Journal:  Rev Bras Ortop       Date:  2013-08-13

3.  No difference in clinical outcome and survivorship after total knee arthroplasty with patellar resurfacing and nonresurfacing after minimum 10-year follow-up.

Authors:  Bin Feng; Yi Ren; Jin Lin; Jin Jin; Wenwei Qian; Xisheng Weng
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.